Showing 1371-1380 of 3472 results for "".
- Global Dermatology Lasers Market Projected to Hit $3.1B by 2029https://practicaldermatology.com/news/global-dermatology-lasers-market-projected-to-hit-31b-by-2029/2474203/The global dermatology lasers market is projected to grow from $2.27 billion in 2025 to $3.1 billion by 2029, according to a market report by The Business Research Company. This growth, according to a press release on the repo
- CAB Gel Reduces Lesions and Preserves Skin Tone in Skin of Colorhttps://practicaldermatology.com/news/cab-gel-reduces-lesions-and-preserves-skin-tone-in-skin-of-color/2474010/A post hoc analysis of pooled Phase 2 and Phase 3 clinical trial data suggests that clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel is effective and well tolerated for the treatment of moderate to severe acne in Black patients.
- Study Links Psoriasis Gene Regulation to Spatial Genome Changeshttps://practicaldermatology.com/news/study-links-psoriasis-gene-regulation-to-spatial-genome-changes/2474007/Results from a new study in the Journal of Investigative Dermatology showed how changes in the 3D chromatin architecture of CD4+ T cells contribute to immune dysregulation in psoriasis. "In this study, the 3D genomic
- Adverse Event Reporting in Dermatology RCTs Falls Short of CONSORT Harms Guidelines: Analysishttps://practicaldermatology.com/news/adverse-event-reporting-in-dermatology-rcts-falls-short-of-consort-harms-guidelines-analysis/2471683/A new review assessing adverse event (AE) reporting in dermatology randomized controlled trials (RCTs) has significant gaps in adherence to the Consolidated Standards of Reporting Trials (CONSORT) Harms guidelines. The systemat
- Charlotte Dermatology, DOCS Dermatology Group Partner, With PGP as Advisorhttps://practicaldermatology.com/news/Charlotte-Dermatology-DOCS-Dermatology-Group-Partner-With-PGP-Advisor/2471624/Physician Growth Partners (PGP) announced it recently advised Charlotte Dermatology on its partnership with DOCS Dermatology Group (backed by SkyKnight Capital). Founded in 1939, Charlotte Dermatology is one of the longest-standing and most trusted dermatology practices in the Greater Char
- Study: 60% Lesion Clearance in Actinic Keratosis Patients Using Topical Bimiralisib Gelhttps://practicaldermatology.com/news/study-60-lesion-clearance-in-actinic-keratosis-patients-using-topical-bimiralisib-gel/2471542/Newly presented interim results from a phase 2 clinical trial evaluating bimiralisib topical gel (2%) saw more than half of patients with actinic keratosis achieving complete or partial lesion clearance. Bimiralisib, a pan-PI3
- Topical Gel Bimiralisib Shows Promise for AK in Interim Resultshttps://practicaldermatology.com/news/Topical-Gel-Bimiralisib-Shows-Promise-AK-Interim-Results/2471537/Interim results from an ongoing Phase 2 clinical trial in actinic keratosis highlighted strong potential for the safety and efficacy of topical gel bimiralisib, a selective pan-PI3K/mTOR inhibitor, Torqur AG announced at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Fl
- Study: AI Model Improves Hair Growth, Texturehttps://practicaldermatology.com/news/ai-model-improves-hair-growth-texture/2471394/An artificial intelligence (AI)-driven platform for customizing hair loss treatments significantly improved hair growth, scalp health, and hair texture in a 24-week study involving women with self-reported hair thinning. The st
- Patient-Centric Guidelines for Generalized Pustular Psoriasis Management Unveiledhttps://practicaldermatology.com/news/patient-centric-guidelines-for-generalized-pustular-psoriasis-management-unveiled/2471251/A global Delphi study has established holistic treatment goals for generalized pustular psoriasis (GPP), integrating both physician and patient perspectives. The consensus study included participants from 24 countries, and acc
- EFFISAYIL 2 Data Suggest Unmet Needs in Generalized Pustular Psoriasis Carehttps://practicaldermatology.com/news/effisayil-2-data-suggest-unmet-needs-in-generalized-pustular-psoriasis-care/2471250/Baseline data from the EFFISAYIL 2 trial suggested that traditional small-molecule therapies fail to adequately address the burden of generalized pustular psoriasis (GPP). The analysis, presented as a poster at Masterclas